- |||||||||| Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Increase in Antibody Titers Following Sars-Cov-2 Vaccination Remains Limited for More Than 3 Years after Final Dose of Anti-CD20 Antibody (GWCC - Thomas Murphy Ballroom 3-4, Level 5) - Nov 5, 2021 - Abstract #ASH2021ASH_1969; We first evaluated antibody titers in 12 healthy volunteers (median age 75.5 years, range 57–82) and three lymphoma patients undergoing R-CHOP therapy (73, 81, and 81 years old) who had received 2 vaccine doses of BNT162b2 at pre-vaccination, 21 days after the first dose and 14 days after the second dose of vaccination...Thirty-four patients had received rituximab-based and 2 had received obinutuzumab-based therapy, with a median of 6 (range 3–20) courses...Alternative protection strategies for these patients are therefore warranted. Although T-cell responses were detected, we recommend that these patients continue to wear a face mask and wash their hands to prevent COVID-19 even after vaccination.
- |||||||||| Kymriah (tisagenlecleucel-T) / Novartis
Tisagenlecleucel Demonstrates Safety, Efficacy and CNS Trafficking in Primary CNS Lymphoma (GWCC - Hall A1) - Nov 5, 2021 - Abstract #ASH2021ASH_1569; P1 The majority of patients demonstrated a response per IPCG, including responses beyond 12 months. Tisagenlecleucel was found to expand in the peripheral blood and CNS with CSF gene signatures suggestive of higher CAR-T cell infiltrates in responding patients.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study (GWCC - Thomas Murphy Ballroom 3-4, Level 5) - Nov 5, 2021 - Abstract #ASH2021ASH_1283; P3 Most pts with uMRD in the Ibr+Ven arm, including those with uIGHV, achieved clearance below 10 -5 , and deeper clearance in PB was mirrored in BM. In the Ibr+Ven arm, clinical relapse was infrequent during the first year off treatment for pts with known MRD status at EOT+3 (whether uMRD or detectable MRD), supported by largely sustained uMRD/MRD levels over the same period.
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
An EZH2 Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of EZH2 Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial (GWCC - B213-B214, Level 2) - Nov 5, 2021 - Abstract #ASH2021ASH_1247; P3 We used the unsupervised k-means algorithm to identify 2 GEP clusters, EZH2_mut and EZH2_WT, comprising 67 patients each ( Fig A ). Patients in the EZH2_mut cluster had significantly longer PFS with CHOP/CVP-based regimens (HR = 4.99, P = 0.002), while the EZH2 GEP signature was not predictive in patients receiving Bendamustine-based treatment ( Fig B ).
- |||||||||| rhIL-15 / National Cancer Institute
Enrollment closed: Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia (clinicaltrials.gov) - Nov 4, 2021 P1, N=1, Active, not recruiting, Patients in the EZH2_mut cluster had significantly longer PFS with CHOP/CVP-based regimens (HR = 4.99, P = 0.002), while the EZH2 GEP signature was not predictive in patients receiving Bendamustine-based treatment ( Fig B ). Suspended --> Active, not recruiting
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen
Clinical, Review, Journal: Pancreatic follicular lymphoma: a report of two cases and literature review. (Pubmed Central) - Nov 4, 2021 Both achieved complete response with induction therapy and opted for maintenance therapy with obinutuzumab. We also conducted a literature review of primary pancreatic follicular lymphoma cases reported over the last 30 years.
- |||||||||| Arzerra (ofatumumab) / Novartis, Genmab
Journal: The selection of variable regions affects effector mechanisms of IgA antibodies against CD20. (Pubmed Central) - Nov 4, 2021 These data characterize the functional activities of human IgA2 antibodies against CD20, which were affected by the selection of the respective variable regions. OBI-IgA2 proved particularly effective in vitro and in vivo, which is potentially relevant in the context of CD47-SIRPα blockade.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Calquence (acalabrutinib) / AstraZeneca
Clinical, P2 data, Journal: Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. (Pubmed Central) - Nov 4, 2021 P2, P3 Acalabrutinib, venetoclax, and obinutuzumab is a highly active and well tolerated frontline therapy for chronic lymphocytic leukaemia. Although the primary endpoint of this study was not met, the high proportion of patients who had undetectable MRD in the bone marrow supports further investigation of this regimen, which is being tested against acalabrutinib-venetoclax and chemoimmunotherapy in an ongoing phase 3 study (NCT03836261).
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial primary completion date, Combination therapy: Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Nov 2, 2021 P1/2, N=87, Active, not recruiting, Trial completion date: Nov 2021 --> Jun 2022 Trial completion date: Aug 2021 --> Aug 2023 | Trial primary completion date: Aug 2020 --> Aug 2022
- |||||||||| Benlysta (belimumab) / GSK, Luveniq (voclosporin) / Aurinia Pharma, Otsuka, Gazyva (obinutuzumab) / Roche, Biogen
Review, Journal: The treatment of lupus nephritis, between consolidated strategies and new therapeutic options: a narrative review (Pubmed Central) - Oct 27, 2021 Recently published (or nearing completion) studies have opened up the possibility of using new drugs in LN. In particular, depletion (Obinutuzumab, anti-CD20 monoclonal antibody) or neutralization (Belimumab, anti-"B-cell activating factor" monoclonal antibody) of B lymphocytes, and the use of a calcineurin inhibitor with a low profile of renal and systemic toxicity (Voclosporin) demonstrated an improvement in renal response in addition to standard therapy.
- |||||||||| Herceptin (trastuzumab) / Roche
Journal, PD(L)-1 Biomarker, IO biomarker: Immune checkpoint markers and anti-CD20-mediated NK cell activation. (Pubmed Central) - Oct 22, 2021 Blockade of TIGIT, TIM3, or both had little impact on RTX-induced NK cell proliferation, degranulation, cytokine production, or activation. Taken together, TIGIT and TIM3 can serve as markers for anti-CD20-mediated NK cell activation, but may not serve well as targets for enhancing the anti-tumor activity of such therapy.
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Trial completion, Metastases: A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) (clinicaltrials.gov) - Oct 20, 2021 P3, N=1401, Completed, The pathogenesis of B-PLL is not completely understood, although mutations in MYC are presumed to play a role. Active, not recruiting --> Completed
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Granulomatous Interstitial Nephritis Secondary to Chronic Lymphocytic Leukemia () - Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_1402; Our patient had partial renal recovery with steroids, obinutuzumab, and venetoclax indicating the efficacy of this regimen compared to rituximab, cyclophosphamide, and steroids. Our case highlights a rare entity of GIN that maybe underdiagnosed in patients with CLL.
- |||||||||| Pixuvri (pixantrone) / Servier, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial completion date, Combination therapy: GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma (clinicaltrials.gov) - Oct 14, 2021 P2, N=70, Active, not recruiting, When considering cost, effectiveness, and toxicities, the preferred treatment strategy for most patients with POD24 follicular lymphoma is ASCT. Trial completion date: Jun 2022 --> Dec 2021
|